ovarian neoplasms, ovary tumour, ovary, fallopian tube, primary peritoneal, cancer, neoplasm, adenocarcinoma, carcinoma, malignant, tumour, metastases, drug therapy, antineoplastic agent, chemotherapy, adjuvant chemotherapy, consolidation chemotherapy, antineoplastic combined chemotherapy protocols, molecular targeted therapy, systemic, biologic, targeted, immunotherapy, hormone, maintenance, therapy, treatment, adriamycin, carboplatin, cisplatin, platinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum, cisdiamminedichloroplatinum, cyclophosphamide, doxorubicin, epirubicin, gemcitabine, irinotecan, isosfamide, paclitaxel, taxane, etoposide, platinum, MEK inhibitor, PD-325901, selumetinib, AZD6244, PD184352, CI-1040, PD035901, TAK-733, binimetinib, MEK162, ARRY-162, ARRY-438162, trametinib, GSK1120212, mekinist, cobimetinib, cotellic, XL518, GDC-0973, poly(ADP-ribose) polymerase inhibitors, olaparib, AZD2281, lynparza, AZD221, veliparib, ABT888, talazoparib, BMN673, nintedanib, iniparib, oregovomab, abagovomab, CA-125, MUC 16, pazopanib, niraparib, MK4827, rucaparib, PF-01367338, AG014699, rapamune, rapamycin, sirolimus, I2190A, AY 22989, cediranib, recentin, AZD2171, antibodies, monoclonal, humanized, bevacizumab, avastin, mTOR inhibitor, temsirolimus, CCI 779, torisel, everolimus, afinitor, certican, RAD001, SDZ-RAD, deforolimus, ridaforolimus, MK8669, AP23573, BRAF inhibitor, PLX8394, vemurafenib, RG7204, R05185426, PLX4032 or PLX-4032, zelboraf, dabrafenib, tafinlar, GSK2118436, tumour-infiltrating lymphocyte therapy, cytokines, IL-2, interferon, IFN-alpha, immune checkpoint inhibitor, thalidomide, sedoval, thalomid, revlimid, lenalidomide, CC5013, S-3APG, pomalidomide, pomalyst, imnovid, CC-4047, bacille calmette-guerin, tamoxifen, tomaxithen, zitazonium, soltamox, novaldex, nolvadex, ICI47699, ICI46474, fareston, fulvestrant, faslodex, ZM 182780, ICI182780, letrozole, femara, CGS-20267, anastrozole, arimidex, ICI D1033, ZD-1033, examestane, aromasin, FCE-24304, cystorelin, dirigestran, factrel, GnRH, gonadoliberin, luliberin, gonadotropin-releasing hormone, kryptocur, LFRH, luteinizing hormone-releasing hormone, angiogenesis inhibitor, aromatase inhibitor, topotecan, hycamtamine, NSC-609699, SKF104864A, oxaliplatin, eloxatin, docetaxol, taxotere, RP-56976, trabectedin, ecteinascidin, yondelis, ET-743, NSC 684766
Stomach Neoplasms (C04.588.274.476.767); Chemotherapy; Adjuvant (E02.186.170); Neoadjuvant Therapy (E02.186.450); Radiotherapy; Adjuvant (E02.186.775); Meta-Analysis as Topic (E05.581.500.501); Review Literature as Topic (L01.178.682.759)
Renal Insufficiency; Chronic (C13.351.968.419.780.750); Renal Insufficiency; Chronic (C12.777.419.780.750); Kidney Failure; Chronic (C12.777.419.780.750.500); Kidney Failure; Chronic (C13.351.968.419.780.750.500)